Time to prophylactic surgery in BRCA1/2 carriers depends on psychological and other characteristics
- PMID: 20921896
- DOI: 10.1097/GIM.0b013e3181f48d1c
Time to prophylactic surgery in BRCA1/2 carriers depends on psychological and other characteristics
Abstract
Purpose: To investigate the medical and psychosocial factors determining the time to prophylactic surgery of unaffected women carriers of a deleterious BRCA1/2 mutation.
Methods: Prospective study on a French national cohort of unaffected BRCA1/2 carriers (N = 244); multivariate Cox proportional hazard modeling.
Results: Median follow-up time was 2.33 years (range, 0.04-6.84 years). Time to surgery was shorter when the psychological impact of BRCA1/2 result disclosure was stated to be higher (P ≤ 0.01). Those who intended to opt for prophylactic surgery before being tested did so faster and more frequently after test disclosure than those who were undecided/opposed. The older the women were, the faster their uptake of risk-reducing salpingo-oophorectomy (adjusted hazard ratio >2.95; P < 0.001) was; the uptake of those with at least two children was also faster (adjusted hazard ratio = 2.51; [1.38-4.55]). Those who opted most quickly for risk-reducing mastectomy more frequently had a younger child at the time of testing (adjusted hazard ratio = 4.63 [1.56-13.74]). Time to surgery was shorter when there was a first-degree relative with ovarian/breast cancer (P ≤ 0.01).
Conclusion: Time to prophylactic surgery depends on the stated psychological impact of disclosure and on women's cognitive anticipation of surgery after adjusting on sociodemographic characteristics.
Similar articles
-
Bilateral prophylactic oophorectomy and bilateral prophylactic mastectomy in a prospective cohort of unaffected BRCA1 and BRCA2 mutation carriers.Clin Breast Cancer. 2007 Dec;7(11):875-82. doi: 10.3816/CBC.2007.n.053. Clin Breast Cancer. 2007. PMID: 18269778
-
Use of genetic testing and prophylactic mastectomy and oophorectomy in women with breast or ovarian cancer from families with a BRCA1 or BRCA2 mutation.J Clin Oncol. 2003 May 1;21(9):1675-81. doi: 10.1200/JCO.2003.09.052. J Clin Oncol. 2003. PMID: 12721241
-
Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation.Lancet. 2000 Jun 10;355(9220):2015-20. doi: 10.1016/s0140-6736(00)02347-3. Lancet. 2000. PMID: 10885351
-
Risk-reducing strategies for women carrying BRCA1/2 mutations with a focus on prophylactic surgery.BMC Womens Health. 2010 Oct 20;10:28. doi: 10.1186/1472-6874-10-28. BMC Womens Health. 2010. PMID: 20961453 Free PMC article. Review.
-
Prevention of breast cancer in women who carry BRCA1 or BRCA2 mutations: a critical review of the literature.Int J Cancer. 2004 Nov 10;112(3):357-64. doi: 10.1002/ijc.20429. Int J Cancer. 2004. PMID: 15382059 Review.
Cited by
-
Patient-Reported Satisfaction after Prophylactic Operations of the Breast.Breast Care (Basel). 2019 Aug;14(4):217-223. doi: 10.1159/000496398. Epub 2019 Feb 15. Breast Care (Basel). 2019. PMID: 31558896 Free PMC article.
-
Psychometric properties of a French version of a Dutch scale for assessing breast and body image (BBIS) in healthy women.BMC Womens Health. 2013 May 16;13:24. doi: 10.1186/1472-6874-13-24. BMC Womens Health. 2013. PMID: 23680028 Free PMC article.
-
French women's breast self-examination practices with time after undergoing BRCA1/2 genetic testing.Fam Cancer. 2012 Jun;11(2):269-78. doi: 10.1007/s10689-012-9512-z. Fam Cancer. 2012. PMID: 22350503
-
Impact of BRCA1/2 mutation on young women's 5-year parenthood rates: a prospective comparative study (GENEPSO-PS cohort).Fam Cancer. 2015 Jun;14(2):273-9. doi: 10.1007/s10689-014-9777-5. Fam Cancer. 2015. PMID: 25550141
-
The evolution of personalized cancer genetic counseling in the era of personalized medicine.Fam Cancer. 2012 Sep;11(3):539-44. doi: 10.1007/s10689-012-9524-8. Fam Cancer. 2012. PMID: 22419176 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous